Tag Archives: Scandinavia

Hot Life Science Investor Mandate 2: CVC of Large Pharma Looking Opportunistically for Life Science Investments

17 Jul

The Corporate Venture Capital arm of a Global Pharmaceutical company provides seed and venture capital to development stage companies within life science and biotechnology. The firm provides pre-seed grants and seed investments to early-stage life science projects in Scandinavia. The firm’s venture investment activities are structured as an open evergreen fund. The firm invests at any stage of development – seed, venture, and growth. The firm also makes late-stage investments in public/private companies with a positive cash flow. The firm can allocate up to $30M per company, but generally allocates between $5M to $20M. The firm seeks companies that are based in North America and Europe. The firm has no current mandate for the number of allocations it plans to make and will evaluate relevant opportunities as they surface.

The firm is opportunistic in the life sciences space. The firm specifically focuses on companies that specialize in the development of novel drugs, new procedures for diagnosis and control of diseases, development of medical devices and instruments, and industrial biotechnology.  The firm is open to all technology and indication areas within these sectors. 

The firm seeks company ownership in return for its seed investments and influential equity ownership for late-stage investments. The firm considers both pre-revenue and revenue generating private and public companies.  The firm is generally opportunistic with the management team, but highly prefers an experienced and qualified management team.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

%d bloggers like this: